

1 **Ready for a BASE jump? Do not neglect SARS-CoV-2 hospitalization and fatality risks in**  
2 **the middle-aged adult population.**

3  
4 **Nathanael Lapidus, MD, PhD<sup>α×1</sup>; Juliette Paireau, PhD<sup>α2,3</sup>; Daniel Levy-Bruhl, MD,**  
5 **PhD<sup>3</sup>; Xavier de Lamballerie, MD, PhD<sup>4</sup>; Gianluca Severi, PhD<sup>5,6</sup>; Mathilde Touvier,**  
6 **PhD<sup>7</sup>; Marie Zins, MD, PhD<sup>8,9</sup>; Simon Cauchemez, PhD<sup>ω2</sup>; Fabrice Carrat, MD, PhD<sup>ω1</sup>;**  
7 **the SAPRIS-SERO study group<sup>+</sup>**

8  
9 <sup>α</sup>: These first authors contributed equally to this article.

10 <sup>ω</sup>: These senior authors contributed equally to this article.

11 <sup>×</sup>: Corresponding author

12 <sup>+</sup>: Members of the SAPRIS-SERO study group are listed in the Technical Appendix

13

14 **Affiliations:**

15 <sup>1</sup> Sorbonne Université, Inserm, Institut Pierre-Louis d'Epidémiologie et de Santé Publique,  
16 Département de Santé Publique, Hôpital Saint-Antoine, APHP.Sorbonne Université, Paris,  
17 France

18 <sup>2</sup> Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris,  
19 France

20 <sup>3</sup> Santé Publique France, French National Public Health Agency, Saint-Maurice, France

21 <sup>4</sup> Unité des Virus Emergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU  
22 Méditerranée Infection, 13005, Marseille, France

23 <sup>5</sup> Department of Statistics, Computer Science and Applications, University of Florence, Italy

24 <sup>6</sup> CESP UMR1018, Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, Villejuif, France

25 <sup>7</sup> Sorbonne Paris Nord University, Inserm U1153, Inrae U1125, Cnam, Nutritional Epidemiology  
26 Research Team (EREN), Epidemiology and Statistics Research Center – University of Paris  
27 (CRESS), Bobigny, France

28 <sup>8</sup> Paris University, Paris, France

29 <sup>9</sup> Paris Saclay University, Inserm UMS 11 Villejuif, France

30

31 **Running Title:** SARS-CoV-2 hospitalization and fatality ratios

32

33 **Keywords:** SARS-CoV-2; COVID-19; Age Specific Death Rate; Adult; France

34

35 **Abstract — 50 words**

36 Seroprevalence results coupled with surveillance data were used to estimate the SARS-CoV-2  
37 infection hospitalization (IHR) and infection fatality ratios (IFR) in France. IHR and IFR were  
38 dramatically high in the very elderly (80-90 years: IHR: 30%, IFR: 11%), but also substantial in  
39 middle-aged adults (40-50 years: IHR: 1.2%, IFR: 0.05%).

40

41 **Text — 744 words**

## 42 **Introduction**

43 The SARS-CoV-2 infection hospitalization ratio (IHR, probability of hospitalization in  
44 infected individuals) and the infection fatality ratio (IFR, probability of death in infected  
45 individuals) are critical parameters in public health decision-making regarding prioritization of  
46 control measures. However, age- and sex-related estimates are scarce, as they need reliable  
47 cumulative estimates of past infections, hospitalizations and deaths. By May 11, 2020, the  
48 cumulative number of COVID-19-related hospitalizations and hospital deaths in France reached  
49 96,000 and 17,000, respectively. This study estimated the age- and sex-specific IFR and IHR in  
50 France for this period based on contemporary SARS-CoV-2 seroprevalence data.

## 51 **Methods**

52 Data from a seroprevalence study performed in May-June 2020 in 20-to 90-year old  
53 subjects were used. This study included subjects from three pre-existing general adult population  
54 cohorts from Île-de-France (N=6,348) and Grand Est (N=3,434), two regions of France with the  
55 highest incidence of COVID-19 during the first wave of the pandemic. (1) All participants from  
56 these cohorts with regular access to online questionnaires were invited to participate in the study  
57 and dried-blood spots were collected in a random sample among them. All samples were  
58 processed with an ELISA test to detect antibodies directed against the spike protein, and for  
59 some of them with an ELISA test to detect antibodies directed against the nucleocapsid protein  
60 and a micro-neutralization assay to detect neutralizing antibodies (technical details were reported  
61 elsewhere (1)). Serological status was estimated with a multiple imputation approach relying on

62 participants' age, sex and serological results for all available tests. Seroprevalence estimates  
63 were calibrated by generalized raking in relation to census data from the general adult  
64 population, excluding nursing home residents who were not part of the cohort target population.  
65 The cumulative numbers of hospital admissions and deaths for COVID-19 were obtained from  
66 the SI-VIC database, the national exhaustive inpatient surveillance system used during the  
67 pandemic. Patients from nursing homes were removed from these counts. Since the median date  
68 of sample collection in the serosurvey was May 14, hospital admissions and deaths were  
69 considered up to May 6 and May 13 to account for estimated 11- and 19- day delays from  
70 infection to hospitalization and seroconversion, respectively, (2,3) and an estimated 7-day delay  
71 from hospitalization to death (SI-VIC data (4)). We report IHR and IFR by sex and 10-year age  
72 class. Multivariable random-effect meta-regression models were fitted to estimate the relative  
73 risks (RR) of hospitalization and death according to age and sex, using age class as a continuous  
74 covariate.

## 75 **Results**

76 The overall estimated IHR and IFR in the French adult population (excluding nursing  
77 homes) were 3.2% (95% confidence interval (CI): 2.8, 3.6) and 0.58% (95% CI: 0.52, 0.65),  
78 respectively. We found a strong log-linear relationship between age and the risk of  
79 hospitalization or death, corresponding to an exponential increase in risk with age (Figure). The  
80 estimated IHR in 20-30, 40-50, 60-70 and 80-90-year-old subjects was 0.46% (95% CI: 0.30,  
81 0.72), 1.2% (95% CI: 0.96, 1.4), 6.9% (95% CI: 5.3, 9.0) and 30% (95% CI: 10, 99), respectively  
82 (RR: 2.1 (95% CI: 1.9, 2.3) per 10-year increase). The estimated IFR in these same age groups  
83 was 0.0077% (95% CI: 0.0050, 0.012), 0.050% (95% CI: 0.041, 0.060), 1.0 (95% CI: 0.81, 1.4)

84 and 11% (95% CI: 3.6, 35), respectively (RR: 3.8 (95% CI: 2.4, 4.2) per 10-year increase). Both  
85 IHR and IFR were higher in men than in women for all age classes: RR: 1.5 (95% CI: 1.1, 2.1)  
86 and 2.5 (95% CI: 1.8, 3.5), respectively.

## 87 **Discussion**

88 We identified an overall IHR of 3.2% and an IFR of 0.58% in the adult population,  
89 excluding those in nursing homes. Though these ratios may be underestimated in the elderly as  
90 nursing home residents are likely to experience poorer outcomes, our estimates are in line with  
91 earlier models (3) and various age-specific IFR estimates, worldwide. (5) The IFR exponentially  
92 increases with age (doubling every 5.2 years) and is higher in men. Both IHR and IFR were  
93 dramatically elevated in the very elderly but this should not obscure substantial estimates in the  
94 young or middle-aged adult population. For example, in 20- to 30-year-old adults, the risk of  
95 death is 8 times that of a skydiving jump (1 per 100,000 jumps (6)) and in 40 to 50-year-olds,  
96 this risk of death is close to that of a BASE jump (1 to 2 per 1000 jumps (6)). From a public  
97 health perspective, these findings support the need for comprehensive preventive measures to  
98 help reduce the spread of the virus, even in young or middle-aged adults.

99 **References**

- 100 1. Carrat F, Lamballerie X de, Rahib D, Blanche H, Lapidus N, Artaud F, et al. Seroprevalence  
101 of SARS-CoV-2 among adults in three regions of France following the lockdown and  
102 associated risk factors: a multicohort study. medRxiv. 2020 Sep 18;2020.09.16.20195693.
- 103 2. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2  
104 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020 Mar 28;
- 105 3. Salje H, Kiem CT, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the  
106 burden of SARS-CoV-2 in France. Science. 2020 Jul 10;369(6500):208–11.
- 107 4. Courtejoie N, Dubost C-L. Parcours hospitalier des patients atteints de la Covid-19 lors de la  
108 première vague de l'épidémie - Ministère des Solidarités et de la Santé. Direction de la  
109 Recherche, des Études, de l'Évaluation et des Statistiques; 2020 Oct. Report No.: 67.
- 110 5. O'Driscoll M, Dos Santos GR, Wang L, Cummings DAT, Azman AS, Paireau J, et al. Age-  
111 specific mortality and immunity patterns of SARS-CoV-2. Nature. 2020 Nov 2;1–9.
- 112 6. Wingsuiting death and risk statistics - infographic danger percentage. [cited 2020 Oct 16].  
113 <http://www.wingsuitfly.com/risk/4572000812>

114

115 **Address for correspondence:** Nathanael Lapidus, Institut Pierre Louis d'Épidémiologie et de  
116 Santé Publique, Faculté de Médecine Sorbonne Université, 27 rue Chaligny, 75571 Paris Cedex  
117 12, France; email: [nathanael.lapidus@inserm.fr](mailto:nathanael.lapidus@inserm.fr)

118 **Funding**

119 The SAPRIS-SERO study was supported by Agence Nationale de la Recherche (ANR), #ANR-  
120 10-COHO-06, Fondation pour la Recherche Médicale (#20RR052-00), Inserm (Institut National  
121 de la Santé et de la Recherche Médicale, #C20-26.

122

123 The authors declare no competing interest.

124

125 **Ethics approval**

126 The SAPRIS-SERO study was approved by the Sud-Méditerranée III ethics committee (approval  
127 #20.04.22.74247) and electronic informed consent was obtained from all participants for DBS  
128 testing.


129

130 **Figure legends**


131 Figure: Infection hospitalization ratio and infection fatality ratio with 95% confidence intervals,  
132 by age class and sex, estimated from seroprevalence data in France (logarithmic scale). Panel A:  
133 Infection hospitalization ratio. Panel B: Infection fatality ratio

**A**

Infection hospitalization ratio

**B**

Infection fatality ratio



◆ Female ◆ Male